• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

DCC-2036

Product ID D0808
Cas No. 1020172-07-9
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $116.00 In stock
5 mg $275.40 In stock
10 mg $436.50 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

DCC-2036 (rebastinib) is an Abl inhibitor that exhibits anticancer activity. In cellular models of chronic myelogenous leukemia (CML), rebastinib induces apoptosis and inhibits cell proliferation. Rebastinib binds the switch control pocket of Abl that is involved in conformational regulation of the kinase domain.

Product Info

Cas No.

1020172-07-9

Purity

≥98%

Formula

C30H28FN7O3

Formula Wt.

553.59

Synonym

DCC2036, Rebastinib

Solubility

DMSO 111 mg/mL (200.5 mM) Ethanol 16 mg/mL (28.9 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D0808 MSDS PDF

Info Sheet

D0808 Info Sheet PDF

References

Shen Y, Shi X, Pan J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One. 2013 Aug 29;8(8):e73059. PMID: 24009732.

Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only